| Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLC (NCT04629027) | Peking University Cancer Hospital & Institute | 2021-03-03 |
| Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer (NCT04828395) | Tianjin Medical University Cancer Institute and Hospital | 2021-03-01 |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers (NCT04464967) | NKGen Biotech, Inc. | 2021-03-01 |
| Breath Analysis in Early Stage Lung Cancer Using Infrared Spectroscopy (NCT04556435) | Breathe BioMedical Inc | 2021-02-25 |
| Establishment of the Human Intestinal and Salivary Microbiota Biobank - Oncologic Diseases (NCT04698161) | Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari | 2021-02-25 |
| A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors (NCT04725331) | Transgene | 2021-02-25 |
| Obstructive Sleep Apnea Influences Efficacy of PD-1-Based Immunotherapy Against Non-Small Cell Lung Cancer (NCT04743752) | Peking University First Hospital | 2021-02-23 |
| A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (NCT04623775) | Bristol-Myers Squibb | 2021-02-17 |
| Heterogeneity of Dendritic Cells in Colon and Non-small Cell Lung Cancer (NCT04789252) | University of Milano Bicocca | 2021-02-09 |
| Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study (NCT04762030) | Shanghai Pulmonary Hospital, Shanghai, China | 2021-02-08 |
| Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer (NCT04736173) | Arcus Biosciences, Inc. | 2021-02-08 |
| Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies (NCT05739006) | Biocad | 2021-02-08 |
| INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (NCT04580485) | Incyte Corporation | 2021-02-03 |
| First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial (NCT05574998) | Qianfoshan Hospital | 2021-02-01 |
| Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy (NCT04716946) | Memorial Sloan Kettering Cancer Center | 2021-01-27 |
| Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors (NCT04609566) | Seagen, a wholly owned subsidiary of Pfizer | 2021-01-26 |
| Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer (NCT04702009) | Shanghai Pulmonary Hospital, Shanghai, China | 2021-01-20 |
| NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial (NCT04698681) | Calithera Biosciences, Inc | 2021-01-19 |
| ENCOrafenib With Binimetinib in bRAF NSCLC (NCT04526782) | Intergroupe Francophone de Cancerologie Thoracique | 2021-01-19 |
| An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (NCT03770299) | Bristol-Myers Squibb | 2021-01-15 |
| A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC (NCT04699968) | Jiangsu HengRui Medicine Co., Ltd. | 2021-01-15 |
| Accelerating Lung Cancer Diagnosis Through Liquid Biopsy (NCT04863924) | University Health Network, Toronto | 2021-01-14 |
| New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy (NCT04564157) | Fundación GECP | 2021-01-13 |
| Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC (NCT05176925) | Fudan University | 2021-01-10 |
| Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge (NCT04335292) | Mark Vincent | 2021-01-06 |
| Functional Lung Imaging With DECT and 4DCT (NCT04702607) | Abramson Cancer Center at Penn Medicine | 2021-01-02 |
| Hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost for BMs of NSCLC (NCT06557187) | Yatian Liu | 2021-01-01 |
| A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (NCT04262375) | University Health Network, Toronto | 2021-01-01 |
| Clinical Effectiveness of Combining Mindfulness-Based Stress Reduction With Exercise Interventione (NCT06224504) | Shanxi Bethune Hospital | 2021-01-01 |
| Evolution of Multiple Primary Lung Cancer (Evolution) (NCT04326751) | Peking University People's Hospital | 2021-01-01 |
| A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (NCT04262388) | University Health Network, Toronto | 2021-01-01 |
| Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC (NCT06369181) | Fudan University | 2021-01-01 |
| Neoadjuvant Immune Checkpoint Inhibitor Combined With Chemotherapy in Non-small Cell Lung Cancer (NCT04945200) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2021-01-01 |
| FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy (NCT04491084) | Albert Einstein College of Medicine | 2021-01-01 |
| Survival Validation and Gene Mutations of N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer (NCT06349252) | Fudan University | 2021-01-01 |
| A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer (NCT04620330) | Verastem, Inc. | 2020-12-31 |
| PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % (NCT04547504) | University Hospital, Brest | 2020-12-22 |
| Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) (NCT04656652) | Daiichi Sankyo | 2020-12-21 |
| Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE) (NCT05049044) | Groupe Francais De Pneumo-Cancerologie | 2020-12-18 |
| A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (NCT04351555) | AstraZeneca | 2020-12-16 |
| Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors (NCT04628780) | Pfizer | 2020-12-16 |
| A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan (NCT05161325) | Bristol-Myers Squibb | 2020-12-15 |
| Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment (NCT04438902) | First Affiliated Hospital of Zhejiang University | 2020-12-12 |
| Central Nervous System(CNS) Efficacy of Dacomitinib (NCT04675008) | Samsung Medical Center | 2020-12-07 |
| Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients (NCT04512430) | Fundación GECP | 2020-12-02 |
| Total-body PET/CT Imaging Using the uEXPLORER in Non-small Cell Lung Cancer Patients Treated by Induction Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiotherapy (NCT04654234) | Sun Yat-sen University | 2020-12-01 |
| Efficacy and Safety of Camrelizumab in Real-World Study (NCT04631146) | Guangdong Association of Clinical Trials | 2020-11-30 |
| A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer (NCT04432207) | Imugene Limited | 2020-11-30 |
| The Canada Lymph Node Score Project: A Crossover Trial (NCT04342377) | St. Joseph's Healthcare Hamilton | 2020-11-30 |
| Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy (NCT04249362) | AstraZeneca | 2020-11-26 |
| A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC (NCT04612673) | China Medical University, China | 2020-11-20 |
| Prediction of Response to Treatment With Immunotherapy + Chemotherapy in Non-Small Cell Lung Cancer (NCT04589013) | University Hospital, Lille | 2020-11-19 |
| Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients (NCT04127110) | European Organisation for Research and Treatment of Cancer - EORTC | 2020-11-17 |
| Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia. (NCT04299048) | Pfizer | 2020-11-17 |
| Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients (NCT04616209) | Precision Biotech Taiwan Corp. | 2020-11-15 |
| A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NCT04958993) | Shandong Cancer Hospital and Institute | 2020-11-12 |
| Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (NCT04644068) | AstraZeneca | 2020-11-12 |
| TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy (NCT04596033) | Genocea Biosciences, Inc. | 2020-11-11 |
| A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC (NCT04580498) | Jiangsu HengRui Medicine Co., Ltd. | 2020-11-10 |
| Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer (NCT04865705) | West China Hospital | 2020-11-10 |
| Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study (NCT04401059) | Tian Xie | 2020-11-09 |
| A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) (NCT04302025) | Genentech, Inc. | 2020-11-06 |
| Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma (NCT04485026) | Wake Forest University Health Sciences | 2020-11-04 |
| A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients (NCT04619563) | Shandong Cancer Hospital and Institute | 2020-11-04 |
| XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer (NCT04622072) | Sihuan Pharmaceutical Holdings Group Ltd. | 2020-11-02 |
| Special Drug Use-results Surveillance of Tabrecta Tablets (NCT04575025) | Novartis Pharmaceuticals | 2020-11-02 |
| Pharmacokinetic Boosting of Osimertinib (NCT03858491) | Academisch Ziekenhuis Maastricht | 2020-11-01 |
| Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial (NCT04553887) | Tianjin Medical University Cancer Institute and Hospital | 2020-11-01 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (NCT04585750) | PMV Pharmaceuticals, Inc | 2020-10-29 |
| Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease (NCT04541407) | University of Colorado, Denver | 2020-10-29 |
| GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy (NCT04601402) | Genome & Company | 2020-10-26 |
| Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2 (NCT04604470) | Maastricht University | 2020-10-20 |
| CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC (NCT04495153) | Candel Therapeutics, Inc. | 2020-10-13 |
| A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer (NCT04619537) | Shandong Cancer Hospital and Institute | 2020-10-08 |
| Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC (NCT03527108) | Fox Chase Cancer Center | 2020-10-08 |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (NCT04591431) | Fondazione per la Medicina Personalizzata | 2020-10-07 |
| A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors (NCT04440735) | Kahr Medical | 2020-10-07 |
| Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC (NCT04500704) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-10-01 |
| Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC). (NCT04690686) | Immunicom Inc | 2020-10-01 |
| Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation (NCT04500717) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-10-01 |
| Key Performance Indicators for the Assessment of NSCLC Patients Pathway (NCT04676321) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2020-10-01 |
| LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT (NCT05919641) | Odense University Hospital | 2020-09-29 |
| A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC (NCT04606771) | AstraZeneca | 2020-09-28 |
| A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (NCT04260802) | Ocellaris Pharma, Inc. | 2020-09-24 |
| Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors (NCT04571632) | Universitair Ziekenhuis Brussel | 2020-09-22 |
| Complication and Lung Function Impairment Prediction Using Perfusion and CT Air Trapping (NCT03885765) | University Hospital, Montpellier | 2020-09-21 |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (NCT04140526) | OncoC4, Inc. | 2020-09-16 |
| Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC (NCT05458726) | Peking Union Medical College | 2020-09-15 |
| Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients) (NCT01817192) | Razor Genomics | 2020-09-11 |
| Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study (NCT04258137) | Institut Bergonié | 2020-09-04 |
| A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors (NCT06630429) | Ohio State University Comprehensive Cancer Center | 2020-09-02 |
| A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment (NCT04560244) | Shandong Cancer Hospital and Institute | 2020-09-01 |
| A Study of Combination Therapy in NSCLC (NCT04544644) | Chinese PLA General Hospital | 2020-09-01 |
| JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy. (NCT04459663) | Li Zhang, MD | 2020-08-31 |
| Liquid Biopsy to Reduce Time to Treatment for Advanced Nonsquamous NSCLC Diagnosed at Outside Sites (NCT04474613) | Case Comprehensive Cancer Center | 2020-08-27 |
| Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer (NCT04210492) | Yale University | 2020-08-26 |
| Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR) (NCT06524427) | Sun Yat-sen University | 2020-08-25 |
| Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT05347628) | Avistone Biotechnology Co., Ltd. | 2020-08-25 |
| Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma (NCT04495894) | Emory University | 2020-08-24 |
| Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2) (NCT04501497) | Chugai Pharmaceutical | 2020-08-21 |